Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETHZ NASDAQ:NEUP NASDAQ:PYXS NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$4.80-2.2%$3.28$0.70▼$17.46$91.26M1.176.44 million shs344,345 shsNEUPNeuphoria Therapeutics$5.21-2.4%$4.64$3.64▼$21.40$28.08M0.7245,369 shs16,846 shsPYXSPyxis Oncology$2.59+14.4%$1.59$0.97▼$5.55$162.09M1.43629,767 shs1.21 million shsVRCAVerrica Pharmaceuticals$7.87-4.5%$5.86$3.28▼$9.82$136.30M1.54127,746 shs43,522 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition-2.24%-7.34%+122.74%+38.73%+479,999,900.00%NEUPNeuphoria Therapeutics-0.74%+1.33%+16.09%+33.17%+8.32%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%VRCAVerrica Pharmaceuticals-2.25%+29.36%+41.58%+19.25%+102.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$4.80-2.2%$3.28$0.70▼$17.46$91.26M1.176.44 million shs344,345 shsNEUPNeuphoria Therapeutics$5.21-2.4%$4.64$3.64▼$21.40$28.08M0.7245,369 shs16,846 shsPYXSPyxis Oncology$2.59+14.4%$1.59$0.97▼$5.55$162.09M1.43629,767 shs1.21 million shsVRCAVerrica Pharmaceuticals$7.87-4.5%$5.86$3.28▼$9.82$136.30M1.54127,746 shs43,522 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition-2.24%-7.34%+122.74%+38.73%+479,999,900.00%NEUPNeuphoria Therapeutics-0.74%+1.33%+16.09%+33.17%+8.32%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%VRCAVerrica Pharmaceuticals-2.25%+29.36%+41.58%+19.25%+102.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETHZFlag Ship Acquisition 1.00SellN/AN/ANEUPNeuphoria Therapeutics 2.25Hold$21.00303.07% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83164.35% UpsideVRCAVerrica Pharmaceuticals 1.75Reduce$17.00115.96% UpsideCurrent Analyst Ratings BreakdownLatest NEUP, ETHZ, PYXS, and VRCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/7/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/24/2026PYXSPyxis Oncology Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.003/24/2026PYXSPyxis Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/9/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETHZFlag Ship Acquisition$4.11M22.20N/AN/A$29.12 per share0.16NEUPNeuphoria Therapeutics$15.65M1.79$0.15 per share34.52$10.11 per share0.52PYXSPyxis Oncology$13.86M11.72N/AN/A$0.86 per share3.01VRCAVerrica Pharmaceuticals$35.58M3.80N/AN/A$1.55 per share5.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/ANEUPNeuphoria Therapeutics-$370K-$4.42N/AN/AN/AN/A-25.98%-18.39%5/19/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.29N/AN/AN/AN/A-101.77%-69.81%5/8/2026 (Estimated)VRCAVerrica Pharmaceuticals-$17.89M-$1.58N/AN/AN/A-50.27%N/A-40.08%5/12/2026 (Estimated)Latest NEUP, ETHZ, PYXS, and VRCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026PYXSPyxis Oncology-$0.35N/AN/AN/A$10.94 millionN/A5/19/2026N/ANEUPNeuphoria Therapeutics-$0.56N/AN/AN/AN/AN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59N/AN/AN/A$4.51 millionN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/11/2026Q4 2025VRCAVerrica Pharmaceuticals-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 million2/17/2026Q2 2026NEUPNeuphoria Therapeutics-$0.56-$0.77-$0.21-$0.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthETHZFlag Ship AcquisitionN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETHZFlag Ship Acquisition1.1110.0710.07NEUPNeuphoria TherapeuticsN/A9.049.04PYXSPyxis OncologyN/A3.413.41VRCAVerrica Pharmaceuticals0.032.592.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETHZFlag Ship Acquisition4.07%NEUPNeuphoria Therapeutics15.90%PYXSPyxis Oncology39.07%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipETHZFlag Ship Acquisition15.10%NEUPNeuphoria Therapeutics1.50%PYXSPyxis Oncology10.60%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/ANEUPNeuphoria TherapeuticsN/A5.39 million5.31 millionN/APYXSPyxis Oncology6062.85 million56.19 millionOptionableVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataNEUP, ETHZ, PYXS, and VRCA HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6 at 5:58 PM | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5 at 4:05 PM | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5 at 3:50 PM | bakersfield.comBVerrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5 at 8:00 AM | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateApril 30, 2026 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by BrokeragesApril 17, 2026 | marketbeat.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks ResearchApril 9, 2026 | marketbeat.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 19, 2026 | tmcnet.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 19, 2026 | businesswire.comVerrica Pharmaceuticals reports 2025 results and YCANTH sales growthMarch 16, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)March 12, 2026 | theglobeandmail.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 11, 2026 | finanznachrichten.deVerrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...March 11, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call TranscriptMarch 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEUP, ETHZ, PYXS, and VRCA Company DescriptionsFlag Ship Acquisition NASDAQ:ETHZ$4.80 -0.11 (-2.24%) As of 05/6/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Neuphoria Therapeutics NASDAQ:NEUP$5.21 -0.13 (-2.43%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Pyxis Oncology NASDAQ:PYXS$2.58 +0.33 (+14.38%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$7.87 -0.37 (-4.47%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
